Goodwin is renowned for its end-to-end patent counsel in the life sciences and technology segments,with the team's portfolio ranging from licensing and collaborations to litigation and regulatory advice. The practice frequently supports venture-backed innovators through financings, M&A and royalty monetisations, leveraging deep sector fluency for strategic asset protection. Practice head Marie Fillon demonstrates strength in cross-border biotech deals.
Legal 500 Editorial commentary
Testimonials
Collated independently by Legal 500 research team.
- ‘Marie Fillon is recommended for IP transactional matters.’
- ‘The team is exceptional, distinguished by its expertise and strategic understanding of business challenges, combined with its availability and ability to handle cases within very short timeframes in a collaborative spirit.'
- ‘Marie Fillon stands out for her sharp technical skills, her rigor, and her ability to provide pragmatic and effective solutions with a strategic mindset. Always responsive and with a collaborative attitude, she makes interactions easy, enriching, and extremely satisfying.’
Key clients
- Andera Partners
- Bpifrance
- Biomunex Pharmaceuticals
- Exor Ventures
- GENFIT
- Germitec
- LocalGlobe
- Micropep Technologies
- Novo Holdings
- One Peak
- Plural
- Sofinnova Partners
Work highlights
Advised listed company GENFIT on a non-dilutive capped royalty financing agreement with HealthCare Royalty (HCRx) for up to €185m in exchange for a portion of the royalties on sales a prescription medicine used to treat primary biliary cholangitis.
Advised Biomunex on its exclusive global licensing agreement with Ipsen for the BMX-502 program.
Advised Stilla Technologies on the signing of a put option agreement for the acquisition, in particular the related IP aspects, of Stilla Technologies by Bio-Rad.
Practice head
Marie Fillon